Single-port Robotic Removal of Gastric Tumor for Gastric Cancer
Official title: Efficacy and Safety Assessment of Single-port Robotic Radical Gastrectomy for Gastric Cancer: a Phase 2a Trial Based on the IDEAL Framework
Run by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · NCT07237126 · Data updated 2026-11-12
This study tests whether a single-port robotic approach to removing gastric tumors is safe and feasible in adults with gastric cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Chongqing, Chongqing Municipality and 1 other locations) |
| Status | Recruiting |
| Started | July 22, 2026 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | August 4, 2026 |
| Trial ID | NCT07237126 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18-75 with confirmed gastric adenocarcinoma, staged without distant metastasis, suitable for potentially curative resection, with good performance status (ECOG 0-1) and acceptable surgical risk.
✕Probably not a fit
Patients with extensive disease, prior major upper abdominal surgery, or poor performance status may not benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-center, phase 2a exploratory study following IDEAL principles to evaluate safety and feasibility of a single-port robot-assisted radical gastrectomy. Researchers analyze intraoperative and postoperative complications, perioperative recovery, and the quality of surgical specimens to determine clinical efficacy. Eligible participants are adults with histologically confirmed gastric adenocarcinoma who may benefit from potentially curative surgery. The trial focuses on intraoperative device- and procedure-related events, postoperative complications, and pathological indices. Outcomes will inform whether this approach could be adopted more broadly.
Why it matters
Potential benefit: If successful, patients may benefit from a less invasive surgical option with potentially similar oncologic control and faster recovery.
How similar studies have gone: Prior studies suggest feasibility for robotic approaches, but single-port techniques in this setting are relatively novel and exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * (1) Age: 18-75 years; (2) Histologically confirmed gastric adenocarcinoma by endoscopic biopsy; (3) Preoperatively staged as either endoscopically unresectable T1, or cT2-4a with or without nodal involvement (N-/+), and no distant metastasis (M0), according to the 7th edition of the AJCC Cancer Staging Manual; (4) Eligible for potentially curative surgical resection; (5) Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1; (6) American Society of Anesthesiologists (ASA) physical status classification of I-III; (7) Provision of written informed consent. Exclusion Criteria: * (1) Pregnant or lactating women; (2) Severe psychiatric disorder; (3) History of prior upper abdominal surgery; (4) Previous gastrectomy, endoscopic submucosal dissection (ESD), or endoscopic mucosal resection (EMR); (5) Preoperative imaging showing regional lymphadenopathy with lymph node(s) larger than 3 cm in diameter; (6) History of another primary malignancy within the past 5 years; (7) Prior neoadjuvant chemotherapy or radiotherapy; (8) History of cerebrovascular or cardiovascular event (e.g., stroke or myocardial infarction) within the past 6 months; (9) Systemic corticosteroid use for more than one month within the past month; (10) Requirement for concomitant surgery for other conditions; (11) Need for emergency surgery due to gastric cancer-related complications (e.g., bleeding, obstruction, or perforation); (12) Participation in another interventional clinical trial previously; (13) Active severe infectious disease; (14) Severe systemic disease.
Where it's running
-
Daping Hospital of Army Medical Universty
Chongqing, China Recruiting -
Daping Hospital
Chongqing, Chongqing Municipality, China Not yet recruiting
Study contacts
- Study coordinator: Fan Li MD
- Email: Levinecq@163.com
- Phone: 0008602368757350
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-assisted CT detection and staging of stomach cancer
This project will test an AI tool that reads routine contrast-enhanced CT scans to detect stomach cancer and assign T1–T4 and N0–N3 stages before surgery.
-
New surgical technique for gastric cancer treatment
This study is testing a new surgical method for gastric cancer to see if it helps patients recover better and have improved nutrition compared to the traditional surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.